Entrectinib May Eventually Be an Option for ROS1 Fusion-Positive NSCLC
Disease control with entrectinib was found to be active and durable in ROS1 fusion-positive NSCLC.
Lung Cancer
Study Supports Standard-Dose RT in Chemoradiotherapy for Some Patients With NSCLC
Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.
Cancer Incidence Has Increased in World Trade Center Responder Cohort
Incidence has increased for all cancer sites combined and for prostate cancer, thyroid cancer, and leukemia.
Lung Nodule Evaluation Guideline Adherence Is High in Multidisciplinary Clinics
The majority of patients with an incidentally detected lung nodule are likely to receive guideline-based evaluation if they are assessed at a multidisciplinary nodule clinic.
Lung Cancer Risk Increased Among Individuals Living in Disadvantaged Neighborhoods
Individuals of low socioeconomic status who reside in disadvantaged neighborhoods with poor living conditions may be at higher risk for lung cancer.
Decline in Lung Cancer Mortality Affects Decreases in Overall Cancer Deaths
Reductions in lung cancer mortality are driving the steady decline in overall cancer deaths.
High BMI Linked to Survival in NSCLC Treated With Atezolizumab
Baseline high body mass index was associated with improved survival in patients with non-small cell lung cancer treated with atezolizumab.
Lung Cancer Screening: Rates Remain Low and Disparities Run High
Despite resources, lung cancer screening with low-dose computed tomography remains underutilized.
Many Patients With Lung Cancer Receive QTc-Prolonging Medications
Receipt of these medications prolonging corrected QT interval limits patients’ eligibility for clinical trials.
Atezolizumab Plus Chemotherapy Approved as First-Line Treatment of Metastatic Non-Squamous NSCLC
The FDA has approved Tecentriq in combination with chemotherapy (Abraxane [paclitaxel protein-bound, nab-paclitaxel; Celgene] and carboplatin) for the first-line treatment of adults with metastatic NSCLC with no EGFR or ALK genomic tumor aberrations.
Next post in Lung Cancer
